2.6. VEGF Polymorphism
The inhibition of angiogenesis through the VEGF/VEGFR pathway is part of the standard of care for most mCRC patients. Regorafenib primarily acts by targeting this angiogenic pathway. Previous publications have investigated the relationship between VEGF and VEGFR gene polymorphisms and clinical responses to anti-angiogenesis therapies [DNA from 47 patients was extracted, and eight single nucleotide polymorphisms (SNPs) located on five genes were investigated. None of the SNPs showed a significant relationship to response to regorafenib in the present cohort (see 